

**bs-13251R****[ Primary Antibody ]**

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

**Galactosylceramidase Rabbit pAb****— DATASHEET —**

<b>Host:</b> Rabbit <b>Clonality:</b> Polyclonal <b>GeneID:</b> 2581 <b>Target:</b> Galactosylceramidase <b>Immunogen:</b> KLH conjugated synthetic peptide derived from human G protein-regulated inducer of neurite outgrowth 2: 81-180/685. <b>Purification:</b> affinity purified by Protein A <b>Concentration:</b> 1mg/ml <b>Storage:</b> 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. <b>Background:</b> GALC is a lysosomal enzyme that hydrolyzes galactose ester bonds in various galactolipids, including galactosylceramide, galactosylsphingosine, lactosylceramide and monogalactosyldiglyceride. Galactolipids contain glucose and/or galactose, and are found in the brain and other nerve tissue, especially the myelin sheath. Galactosylceramide is a major lipid in myelin, kidney, and epithelial cells of the small intestine and colon. Mutations in the GALC gene that compromise protein function correlate to Krabbe disease (globoid cell leukodystrophy, GLD). GLD is an autosomal recessive condition that affects approximately 1 in 150,000 infants and results in progressive destruction of the nervous system. The “twitcher” mouse is a model system for GLD; the genotype is a premature stop codon (W339X) in the galactosylceramidase (GALC) gene that abolishes enzymatic activity. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.	<b>Isotype:</b> IgG <b>SWISS:</b> P54803 <b>Applications:</b> <b>IHC-P</b> (1:100-500) <b>IHC-F</b> (1:100-500) <b>IF</b> (1:100-500)  <b>Reactivity:</b> Human, Mouse, Rat (predicted: Rabbit, Pig, Sheep, Cow, Chicken, Dog, Horse)  <b>Predicted MW.:</b> 73 kDa  <b>Subcellular Location:</b> Cytoplasm
---	--

**— VALIDATION IMAGES —**

Tissue/cell: Rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation: Anti-GALC Polyclonal Antibody, Unconjugated(bs-13251R) 1:500, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining



Tissue/cell: human kidney tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation: Anti-GALC Polyclonal Antibody, Unconjugated(bs-13251R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining

**— SELECTED CITATIONS —**

- **[IF=3.171]** Yang-Yang Wang. et al. Nogo-A aggravates oxidative damage in oligodendrocytes. Neural Regen Res. 2021 Jan;16(1):179 IF ;Rat. 32788474

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.